Gersizangitide is under clinical development by AsclepiX Therapeutics and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gersizangitide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gersizangitide (AXT-107) is under development for the treatment of wet age related macular degeneration, retinal neovascularization, choroidal neovascularization and macular edema due to retinal vein occlusion and diabetic macular edema. It is administered by Intravitreal route. It is a biomimetic peptide and acts by targeting vascular endothelial growth factor (VEGF-A) and vascular endothelial growth factor (VEGF-C) and tie2.
AsclepiX Therapeutics overview
AsclepiX Therapeutics is a biotechnology company that creates novel therapeutics to transform the treatment of retinal diseases and cancer. The Company is headquartered in Baltimore, Maryland, the US.
For a complete picture of Gersizangitide’s drug-specific PTSR and LoA scores, buy the report here.